HER2-Positive Breast Cancer: New Findings, Expanded Options, and an Evolving Treatment Paradigm

Download All
Learn from the experts how to leverage new and established HER2-targeting agents for optimal management of HER2+ early and metastatic breast cancer with these downloadable slides and on-demand Webcast.
Neelima Denduluri, MD, FASCO
Lee Schwartzberg, MD, FACP

On-Demand Webcast

Watch this on-demand Webcast capturing expert presentations focused on the latest treatment strategies for patients with HER2+ breast cancer in the early and metastatic settings.

Downloadable Slidesets

Download this short slideset of essential highlights from a live presentation on the latest developments in managing HER2-positive breast cancer.

Neelima Denduluri, MD, FASCO Lee Schwartzberg, MD, FACP Released: July 8, 2020

Review the latest clinical data and expert guidance on management of HER2-positive early-stage breast cancer, including how to assess risk and plan (neo)adjuvant therapy; treat lower- vs higher-risk disease; and optimally manage adverse events associated with HER2-targeted therapy.

Lee Schwartzberg, MD, FACP Released: June 30, 2020

Get up to date on current and emerging HER2-targeted TKIs and antibody–drug conjugates for HER2-positive metastatic breast cancer across multiple lines of therapy.

Neelima Denduluri, MD, FASCO Released: June 30, 2020
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Puma Biotechnology, Inc.
Seattle Genetics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue